Several studies have demonstrated links between cigarette smoking and prostate cancer. To better understand the influence of smoking on prostate cancer progression and treatment, Michael Zelefsky, MD, of the Memorial Sloan Kettering Cancer Center in New York City and Professor of Radiation Oncology, and his colleagues studied 2358 patients who underwent external beam radiotherapy for prostate cancer between 1988 and 2005. Of these, 2156 had a history of smoking. Patients were classified as never smokers, current smokers, former smokers, and current smoking unknown.
Over a median follow-up of nearly eight years, patients who were current smokers had a 40% increased risk of cancer relapse, as well as more than 2-times increased risks of cancer spread and cancer-related death, compared with patients who were never smokers. In addition, current and former smokers had a higher likelihood of experiencing side effects, such as urinary toxicity, related to radiotherapy. Examples of urinary toxicity include urinary retention, urinary incontinence, and bladder hemorrhage.
“Less optimal tumor control outcomes among smokers could possibly be explained by the influence of less oxygen concentration within the treated tumors among smokers, which is known to lead to less sensitivity of the cells being killed off by radiation treatments,” Dr. Zelefsky noted. “Our findings point to the importance of physicians counseling their patients regarding the potential harms of smoking interfering with the efficacy of therapies and for increased risks of side effects.”
Media wishing to receive a PDF of this article may contact [email protected] (Would you prefer to access this paper instantly? You can register for a login to our Press Room here.)
Full citation: “Cigarette smoking during external beam radiation therapy for prostate cancer is associated with an increased risk of prostate cancer-specific mortality and treatment-related toxicity.” Emily Steinberger, Marisa Kollmeier, Sean McBride, Caroline Novak, Xin Pei, and Michael J. Zelefsky. BJU International; Published Online: January 27, 2015 (DOI: 10.1111/bju.12969).
To arrange an interview with the authors, please contact Courtney DeNicola Nowak of the Memorial Sloan Kettering Cancer Center’s press office at [email protected] or +1 (212) 639-3573.
About the Journal:
BJUI is a highly respected international medical journal that aims to provide the very highest standard of research and clinical information for the urological community, promoting awareness of new advances and supporting best practice in urology. Every issue gives invaluable practical information in the form of original articles, reviews, comments, translational science and surgical education articles on all aspects of urology.
For more information, please visit BJU International.
Wiley is a global provider of content-enabled solutions that improve outcomes in research, education, and professional practice. Our core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners.
Founded in 1807, John Wiley & Sons, Inc. (NYSE: JWa, JWb), has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace. Wiley’s global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company’s website can be accessed at http://www.wiley.com.
Evelyn Martinez (US) +1 201 748 6358
Tom Griffin (UK) +44 (0) 1865 476213